Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.

Fabio Efficace,Pasquale Niscola,Andrea Patriarca,Francesco Cottone,Giuseppe A. Palumbo,Massimo Breccia,Giovanni Caocci,Uwe Platzbecker,Giorgina Specchia,Reinhard Stauder,Luana Fianchi,Grazia Sanpaolo,Duška Petranović,Chiara Frairia,Jo Caers,Valeria Santini,Micaela Bergamaschi,Isabella Capodanno,Nicola Di Renzo,Marco Vignetti

Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.

2019

e18220Background: Whilst a substantial body of knowledge is available on the genetics and biology of MDS, very little is known on quality of life of these patients. We aimed to 1) examine patient-r...

Keywords:

Physical therapy
Disease
Myelodysplastic syndromes
Internal medicine
Medicine
in patient
Quality of life
disease risk
symptom prevalence

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations